ArticleObesity science & practice2025
Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.
Article in Obesity science & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of obstructive sleep apnea-hypopnea syndrome on myocardial mechanics in obese patients.Frontiers in cardiovascular medicine · 2026Article
- Effect of Glucagon-Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea.Obesity science & practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Glucagon-like peptide-1 receptor (GLP-1R) agonists are well-established therapies for obesity and type 2 diabetes mellitus (T2DM). Emerging evidence also suggests their potential role in managing obstructive sleep apnea (OSA). This study aimed to investigate the association between GLP-1R agonists and OSA using genetic evidence. Methods: Cis-expression quantitative trait loci (cis-eQTLs) associated with the Results: IVW analysis showed that genetically predicted GLP-1R agonist exposure was associated with a reduction in BMI ( Conclusion: This study provides genetic evidence supporting the protective role of GLP-1R agonists against OSA, highlighting their potential as a therapeutic strategy for OSA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.